2,3-Dimethoxy-4,5-methylenedioxyamphetamine

2,3-Dimethoxy-4,5-methylenedioxyamphetamine (also known as DMMDA) is a psychedelic drug and a substituted amphetamine. It is a member of the DOx family of compounds which are known for their high potency, long duration, and mixture of psychedelic and stimulant effects.

Chemistry

DMMDA is a chemical compound with the systematic name 1-(2,3-dimethoxy-4,5-methylenedioxyphenyl)-2-propanamine. It belongs to the class of organic compounds known as amphetamines and derivatives. These are organic compounds containing or derived from 1-phenylpropan-2-amine.

Pharmacology

DMMDA acts as a serotonin receptor agonist. The psychedelic effects are believed to come from DMMDA's efficacy at the 5-HT2A receptor. However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive.

Effects

The effects of DMMDA can vary widely depending on the dose and individual's physiology. Common effects include hallucinations, enhanced colors, increased appreciation for music, and emotional introspection. At higher doses, effects can include significant time distortion, tactile enhancement and synesthesia.

History

DMMDA was first synthesized by Alexander Shulgin and described in his book PiHKAL. Shulgin listed the dosage range as 20–100 mg and the duration as 4–8 hours. He reported that DMMDA produces an increase in blood pressure and heart rate, and causes mydriasis.

Legality

In the United States, DMMDA is classified as a Schedule I drug under the Controlled Substances Act. This means it has a high potential for abuse, no currently accepted medical use in treatment in the United States, and a lack of accepted safety for use under medical supervision.

See also

• Psychedelic drug
• Substituted amphetamine
• DOx
• Alexander Shulgin
• PiHKAL